News & Trends

The NFL season opens Wednesday and runs 18 weeks. A Wegovy dose escalation runs 16.

By the US Health Digest editorial team · Published September 4, 2026 · Every claim linked to its primary source

The NFL's 18-week, 272-game regular season opens Wednesday, September 9 at 8:20 p.m. ET, the defending champion Seattle Seahawks hosting the New England Patriots at Lumen Field on NBC. From that night to Super Bowl LXI on February 14, 2027 is 158 days and 23 Sundays. The dose-escalation schedule in Table 1 of the Wegovy injection label runs 16 weeks. Set the two calendars side by side and they differ by two weeks.

This page reports what league announcements, labels, trials and federal documents say. It is not a diet plan, not advice about drinking, and not a reason to change any medicine.

What is actually happening on September 9

Per the league's schedule announcement, "the defending Super Bowl Champion Seattle Seahawks host the New England Patriots at Lumen Field on Wednesday, September 9 (8:20 p.m. ET, NBC)." NFL.com and NBC Sports confirm the slot. It is a rematch of Super Bowl LX, won by Seattle 29–13 on February 8, 2026 at Levi's Stadium. The Wednesday is logistics. ESPN, reporting the schedule release, notes: "The last time the NFL season started on a Wednesday was in 2012 to accommodate then-President Barack Obama's speech at the Democratic National Convention the following day." This time it clears Thursday, September 10 (8:35 p.m. ET, Netflix) for the Rams and 49ers at the Melbourne Cricket Ground.

The rest of the calendar is the part that concerns a health publication. Per the league, the season runs 18 weeks and 272 games and closes with 16 division games in Week 18 — three on Saturday, January 9, 2027 and 13 on Sunday, January 10 — before Super Bowl LXI on February 14, 2027 at SoFi Stadium. The wild-card round is scheduled for January 16–18. Inside the regular season: a Thanksgiving tripleheader on November 26, two games on Christmas Day. Five months of appointments, nearly all of them social.

Eighteen weeks of season, sixteen weeks of escalation

The current Wegovy prescribing information on DailyMed (document effective June 18, 2026) tells prescribers to "Follow the dosage escalation in Table 1 to reduce the risk of gastrointestinal adverse reactions": four four-week steps — 0.25, 0.5, 1 and 1.7 mg — with maintenance from week 17. That is Table 1, which governs the injection; the same document sets a separate 30-day-step schedule for Wegovy tablets, so everything below is about the injection only. It adds a clause that matters more than the doses do: "If patients do not tolerate a dose during dosage escalation, consider delaying dosage escalation for 4 weeks."

The overlap matters because escalation is when gastrointestinal adverse reactions are most in play. In STEP 1 (n=1,961, 68 weeks, treatment-policy primary estimand), mean weight change was −14.9% on semaglutide against −2.4% on placebo, and "more participants in the semaglutide group than in the placebo group discontinued treatment owing to gastrointestinal events (59 [4.5%] vs. 5 [0.8%])." That last pair is a count in the trial's safety reporting, not an estimand-based estimate. The escalation window, for a first dose this week, runs from the opener to New Year.

Where hunger stops being the cue

What the drug does is on the label: "Semaglutide decreases calorie intake. The effects are likely mediated by affecting appetite," and "Semaglutide delays gastric emptying." A medicine that works on appetite is one you assess by consulting your appetite; a season is the opposite arrangement — the eating is timed by a broadcast window — which is a measurement problem rather than a moral one: for 23 Sundays, "am I hungry?" is answered by the kickoff. No label addresses that. STEP 1 also gave participants the drug plus lifestyle intervention, per the trial record; what it changes at the plate is in eating on a GLP-1 and protein-first eating, and the movement half is in the ENDO 2026 step-count poster.

The alcohol thread, as the federal documents now stand

The familiar rule is not in the current guidance. The Dietary Guidelines for Americans, 2025–2030, released January 7, 2026, carry no numeric drink limits. The whole alcohol section is two bullets, 63 words: "Consume less alcohol for better overall health," plus a list of people who "should completely avoid alcohol," including "people taking medications or with medical conditions that can interact with alcohol." We documented that search, edition against edition, in what the two documents actually say.

Federal sources have not converged. CDC's moderate alcohol use page, still live on September 4, 2026, keeps the old figures: "For men—two drinks or less in a day. For women—one drink or less in a day." NIAAA, read the same day, defines no moderate level at all, but keeps one threshold on a shorter clock: binge drinking is a pattern that brings blood alcohol concentration "to 0.08%… or higher," which "For a typical adult… corresponds to consuming five or more drinks (male), or four or more drinks (female), in about two hours." Two hours is about half a game — an observation about how the definitions are built, not a recommendation from us.

The guidelines' clause about interacting medications does not resolve to this class. Our full-text sweep of twelve GLP-1 labels on August 30, 2026, in alcohol on a GLP-1, found no alcohol-interaction warning and no drinking advice on any product approved for weight management; re-reading the four labels currently approved in the US for weight management — Wegovy, Zepbound, Saxenda and Foundayo — on September 4, 2026 found no alcohol entry in any Drug Interactions section and nothing said to patients about drinking.

Drinking plus GI side effects: thin, and worth saying so

Three things exist, and none of them is about a Sunday:

• One retrospective model, in the wrong population. A single-centre cohort of 215 adults with type 2 diabetes in China (Front Endocrinol 2025, PMID 41255528) found alcohol consumption — "regular intake of any alcoholic beverage for more than six months" — an independent risk factor for semaglutide-associated gastrointestinal adverse events, odds ratio 2.941 (95% CI 1.304–6.633, P=0.009). Its authors note that "the absence of external validation limits the assessment of the generalizability."
• One 20-person pilot. Sci Rep, October 2025 (PMID 41093891) gave 20 adults with obesity, half on a GLP-1, a fixed alcohol challenge and saw a delayed rise in breath alcohol concentration — preliminary evidence, its authors say, of a peripheral mechanism.
• What the label does connect. Wegovy's Section 5.5 attributes postmarketing acute kidney injury reports to one route: gastrointestinal adverse reactions "leading to dehydration such as nausea, vomiting, or diarrhea." Alcohol is not named there.

Searching PubMed and the ClinicalTrials.gov API on September 4, 2026, nearly every registered trial pairing a GLP-1 with alcohol enrols people with alcohol use disorder or alcohol-related liver disease rather than people taking these drugs for weight. The Lancet trial of May 2026 (PMID 42070571) tested semaglutide 2.4 mg in 108 people with alcohol use disorder and obesity, cutting heavy drinking days by an estimated 13.7 percentage points more than placebo (95% CI −22.0 to −5.4; p=0.0015): real finding, defined group. The single exception we found is NCT07758231, which plans to enrol five adults with a BMI of 30–45 already taking prescribed tirzepatide and screens alcohol use disorder out. It is listed as not yet recruiting with an estimated October 2026 start, and it measures alcohol pharmacokinetics rather than gastrointestinal tolerability. That is the whole of it.

How to think about an 18-week stretch

Questions for a prescriber, not instructions from us.

• Given my start date and my product's label, where on the escalation do November 26 and December 25 fall — and where if a step is delayed four weeks?
• Am I also taking an insulin-containing combination? Checking the labels again on September 4, 2026, the only GLP-1 products whose labeling says anything to patients about drinking were the two insulin combinations, Soliqua 100/33 and Xultophy 100/3.6.
• The label's table of adverse reactions occurring in at least 2% of adults on Wegovy injection 2.4 mg for weight reduction, and more often than on placebo, lists nausea at 44% (placebo 16%), diarrhea at 30% (16%) and vomiting at 24% (6%), and Section 5.5 ties those reactions to dehydration. What symptoms should prompt a call rather than a wait?

Frequently asked questions

Do the current federal dietary guidelines still set a daily drink limit?

No. The Dietary Guidelines for Americans, 2025–2030, released January 7, 2026, contain no numeric alcohol limits; the whole alcohol section is two bullets and 63 words. CDC's moderate alcohol use page was still publishing the older figures on September 4, 2026: two drinks or less in a day for men, one drink or less in a day for women.

Does drinking make GLP-1 nausea worse?

The evidence is thin and we will not fill the gap with a mechanism. A single-centre retrospective study of 215 adults with type 2 diabetes in China reported alcohol consumption, defined as regular intake for more than six months, as an independent risk factor for semaglutide-associated gastrointestinal adverse events, odds ratio 2.941. Its authors note there was no external validation, and it is not a weight-management population. No FDA-approved GLP-1 used for weight management carried an alcohol interaction in its labeling when we checked the labels on September 4, 2026.

Will a GLP-1 make me want to drink less over the season?

Nobody can tell you that. The strongest randomised evidence is a Lancet trial published in May 2026 in 108 people who had alcohol use disorder and obesity, where semaglutide 2.4 mg reduced heavy drinking days by 13.7 percentage points more than placebo. Nearly every registered trial we found on September 4, 2026 enrols people with alcohol use disorder or alcohol-related liver disease; the one exception, NCT07758231, is a five-person pharmacokinetics study that has not begun recruiting. The effect is unquantified for anyone else.

The bottom line

One calendar runs 18 weeks and the other 16. The point of laying them side by side is not that anyone should line them up, but that the stretch of a label where the dose is still climbing is also, this autumn, the stretch of the calendar carrying the most scheduled eating — which is worth knowing before it arrives rather than during. More in our GLP-1 FAQ and GLP-1 side effects.